Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab)

被引：45

作者：

Kain, S ^{[1
]}

Copeland, TS ^{[1
]}

Leahy, MF ^{[1
]}

机构：

[1] Fremantle Hosp, Dept Haematol, Fremantle, WA, Australia

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 119卷 / 02期

关键词：

rituximab; refractory autoimmune (acquired) haemophilia; factor VIII inhibitor;

D O I：

10.1046/j.1365-2141.2002.03835_5.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：578 / 578

页数：1

共 50 条

[31] Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature [J].

Pels, H ;

Schulz, H ;

Schlegel, U ;

Engert, A .

ONKOLOGIE, 2003, 26 (04) :351-354

[32] Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas [J].

Domingo-Domènech, E ;

González-Barca, E ;

Estany, C ;

Sureda, A ;

Besalduch, J ;

de Sevilla, AF .

HAEMATOLOGICA, 2002, 87 (11) :1229-1230

[33] Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab) [J].

Heiligenhaus, Arnd ;

Miserocchi, Elisabetta ;

Heinz, Carsten ;

Gerloni, Valeria ;

Kotaniemi, Kaisu .

RHEUMATOLOGY, 2011, 50 (08) :1390-1394

[34] Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia [J].

Nightingale, Ginah .

ANNALS OF PHARMACOTHERAPY, 2011, 45 (10) :1248-1255

[35] Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab [J].

Chen, Lucia Y. ;

Shah, Raakhee ;

Cwynarski, Kate ;

Lambert, Jonathan ;

McNamara, Christopher ;

Mohamedbhai, Sajir G. ;

Virchis, Andres ;

Townsend, William ;

D'Sa, Shirley ;

Ardeshna, Kirit M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) :462-465

[36] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis [J].

Michael Zhong ;

Anneke van der Walt ;

Maria Pia Campagna ;

Jim Stankovich ;

Helmut Butzkueven ;

Vilija Jokubaitis .

Neurotherapeutics, 2020, 17 :1768-1784

[37] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].

Boye, J ;

Elter, T ;

Engert, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535

[38] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis [J].

Zhong, Michael ;

van der Walt, Anneke ;

Campagna, Maria Pia ;

Stankovich, Jim ;

Butzkueven, Helmut ;

Jokubaitis, Vilija .

NEUROTHERAPEUTICS, 2020, 17 (04) :1768-1784

[39] The anti-CD20 antibody Rituximab reduces the Th17 response [J].

van de Veerdonk, Frank L. ;

Lauwerys, Bernard ;

DiPadova, Franco ;

Marijnissen, Renoud J. ;

Koenders, Marije I. ;

Gutierrez-Roelens, Ilse ;

Durez, Patrick ;

Netea, Mihai G. ;

van der Meer, Jos W. M. ;

van den Berg, Wim B. ;

Joosten, Leo A. B. .

CYTOKINE, 2009, 48 (1-2) :98-98

[40] Treatment of multiple sclerosis with Anti-CD20 antibodies [J].

Barun, Barbara ;

Bar-Or, Amit .

CLINICAL IMMUNOLOGY, 2012, 142 (01) :31-37

← 1 2 3 4 5 →